CAMP4 Therapeutics Corporation (CAMP) outlined its planned Phase 1/2 ASCEND study of CMP-002 for SYNGAP1-related disorder. The randomized, double-blind study will compare intrathecal CMP-002 with a sham pinprick in a 3:1 allocation across three dose cohorts, followed by an open-label extension. The company expects first dosing by the end of 2026 and targets topline data in the first half of 2028.
The planned trial includes participants aged 2 to less than 18 and more than 11 sites across at least nine countries; sites in the United Kingdom, Australia and Argentina have regulatory approval, while European Union sites are under review. CAMP4 described its SHANK3 program for Phelan-McDermid syndrome as preclinical, estimates more than 45,000 patients in the United States, and expects to designate a development candidate in 2027. It is also evaluating programs for two additional early-stage central nervous system haploinsufficient diseases.
Camp4 Therapeutics Corp (CAMP) reported that Chief Financial Officer Kelly Gold filed a Form 4 showing an open-market purchase associated with her household of 10,000 shares of Common Stock on August 31, 2026, at a weighted average price of $3.96 per share, in multiple trades between $3.88 and $4.00. These shares are held in a brokerage account in the name of her spouse, over which she does not exercise investment control and for which she disclaims beneficial ownership except for any pecuniary interest. Separately, Gold is reported to hold 76,467 shares directly, including 2,039 shares previously acquired under Camp4 Therapeutics Corporation’s Employee Stock Purchase Plan.
Camp4 Therapeutics Corp (CAMP) is the subject of an Amendment No. 3 to Schedule 13D filed by several 5AM venture funds and managing members Andrew J. Schwab and Dr. Kush Parmar, updating their beneficial ownership and recent trading activity in Camp4 common stock.
The reporting group’s beneficial ownership is based on 62,753,200 shares outstanding as of August 12, 2026. Schwab is deemed to beneficially own 6,379,125 shares (including 9,000 vested options), representing 9.99% of the common stock, and Parmar is deemed to beneficially own 6,370,125 shares, or 9.98%. Ventures VI holds 2,033,270 shares, Ventures VII holds 2,941,176 shares plus Pre-Funded Warrants for up to 3,179,558 shares, and Opportunities II holds 302,770 shares.
The filing details recent sales by Ventures VI between August 19 and 27, 2026, including open market sales totaling over 190,000 shares at weighted average prices around $4.50–$4.76 and a block sale of 400,000 shares at $4.04. A Beneficial Ownership Blocker in the Pre-Funded Warrants limits Ventures VII’s exercise so that, after exercise, affiliated holders do not exceed 9.99% of Camp4’s outstanding common stock.
Camp4 Therapeutics Corp (CAMP) director Andrew J. Schwab, through an affiliated investment fund, reported selling 400,000 shares of common stock on 2026-08-27 at $4.04 per share. After this sale, 5AM Ventures VI, L.P. held 2,033,270 shares, and affiliated funds 5AM Ventures VII, L.P. and 5AM Opportunities II, L.P. held 2,941,176 and 302,770 shares, respectively. The filing states these positions are held indirectly through 5AM entities and that Schwab disclaims beneficial ownership beyond his pecuniary interest.
Camp4 Therapeutics Corp (CAMP) director Andrew J. Schwab reported a small sale of 10 shares of common stock on 2026-08-24 at $4.50 per share. The shares are held indirectly through 5AM Ventures VI, L.P., with Schwab reporting shared voting and investment power through his role at its general partner and disclaiming beneficial ownership except for his pecuniary interest.
Following this transaction, entities associated with Schwab reported indirect holdings of 2,433,270 shares via 5AM Ventures VI, L.P., 2,941,176 shares via 5AM Ventures VII, L.P., and 302,770 shares via 5AM Opportunities II, L.P. The filing does not indicate use of a Rule 10b5-1 trading plan.
Camp4 Therapeutics Corp (CAMP) reports that director Andrew J. Schwab, through affiliated fund 5AM Ventures VI, L.P., sold 191,865 shares of Common Stock over August 19–21, 2026 in open-market or private transactions. The sales were indirect, by 5AM Ventures VI, with Schwab disclaiming beneficial ownership beyond his pecuniary interest.
The sales comprised 45,147 shares on August 19 at a weighted average $4.76 (individual trades from $4.75–$5.00), 114,700 shares on August 20 at a weighted average $4.54 (from $4.50–$4.91), and 32,018 shares on August 21 at a weighted average $4.50 (from $4.50–$4.53). Separate holding entries show 2,941,176 shares held by 5AM Ventures VII, L.P. and 302,770 shares held by 5AM Opportunities II, L.P., both reported as indirect interests with similar beneficial-ownership disclaimers.
Camp4 Therapeutics Corp (CAMP) reported an insider sale by Chief Scientific Officer Daniel Tardiff. On August 19, 2026, he sold 1,738 shares of common stock in a sale characterized as an open market or private transaction at $4.76 per share. Following this transaction, his reported direct holdings of common stock from this lot were 0 shares. The shares had been previously acquired through the company’s Employee Stock Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026 in a transaction described as exempt under Rule 16b-3(c).
Camp4 Therapeutics Corporation (CAMP) received an amended Schedule 13D/A from Polaris-affiliated funds and individuals updating their ownership in the company’s common stock. The amendment states it is being filed to reflect a lower ownership percentage resulting from dilution caused by Camp4’s sales of additional common shares since the prior amendment.
Polaris Management Co. VII, L.L.C., as general partner of Polaris Partners VII, L.P. and Polaris Entrepreneurs’ Fund VII, L.P., reports beneficial ownership of 3,023,161 shares, or 4.8% of Camp4’s common stock, all with shared voting and dispositive power. Polaris Partners VII, L.P. holds 2,825,500 shares (about 4.5%), and Polaris Entrepreneurs’ Fund VII, L.P. holds 197,661 shares (about 0.3%). Polaris Partners X, L.P. reports 909,090 shares (about 1.4%), with control through Polaris Partners GP X, L.L.C.
Individually, board member Amir Nashat is deemed to beneficially own an aggregate of 3,932,251 shares, representing approximately 6.3% of Camp4’s outstanding common stock, through interests in these Polaris entities. All reported ownership percentages are based on 62,753,200 common shares outstanding as of August 12, 2026, as reported by Camp4 in its Form 10-Q.
Camp4 Therapeutics Corp (CAMP) received a notice that affiliate Daniel Tardiff, through J.P. Morgan Securities LLC as agent, plans to sell 1,738 shares of common stock under Rule 144. The proposed sale is valued at approximately $8,275.55 with an anticipated sale date of August 19, 2026. The filing also notes an earlier 434-share ESPP issuance on July 2, 2026 for cash.
Balyasny Asset Management and related entities reported beneficial ownership of Camp4 Therapeutics Corp. common stock. Through Atlas Diversified Master Fund, Ltd. and Atlas Private Holdings (Cayman) Ltd., the reporting group may be deemed to beneficially own 2,591,097 shares of common stock. This represents approximately 4.99% of the outstanding shares, based on 51,925,800 shares outstanding as of May 6, 2026. The position includes common shares and shares issuable upon exercise of warrants that are subject to a 4.99% Beneficial Ownership Limitation, which blocks warrant exercises that would push ownership above that level. The reporting persons have sole voting and dispositive power over the reported shares and disclose that the underlying funds, ADMF and APHC, are entitled to dividends and sale proceeds.